Prevalence of nonrecommended screening for prostate cancer and breast cancer in the United States: A nationwide survey analysis

JAMA Oncology

Volumn 2, Issue 4, 2016, Pages 543-545

  Abdollah, Firas ^a   Sun, Maxine ^b   Sammon, Jesse D ^a   Choueiri, Toni K ^c   Menon, Mani ^a   Weissman, Joel S ^b   Trinh, Quoc Dien ^b  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; BLOOD; BREAST NEOPLASMS; EARLY CANCER DIAGNOSIS; FEMALE; HUMAN; MALE; MAMMOGRAPHY; PREVALENCE; PROSTATIC NEOPLASMS; QUESTIONNAIRE; UNITED STATES; UTILIZATION;

AGED; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MAMMOGRAPHY; PREVALENCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVEYS AND QUESTIONNAIRES; UNITED STATES;

EID: 84986274548     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.5871     Document Type: Letter

References (6)

1. National Comprehensive Cancer Network. Breast cancer screening and diagnosis. Version I.2014. http://www.nccn.org/professionals/physician-gls/pdf/breast-screening.pdf. Accessed July 24, 2014.
2. National Comprehensive Cancer Network. Prostate cancer early detection. Version I.2014. http://www.nccn.org/professionals/physician-gls/pdf/prostate-detection.pdf. Accessed July 24, 2014.
3. Ong MS, Mandl KD. National expenditure for false-positive mammograms and breast cancer overdiagnoses estimated at $4 billion a year. Health Aff (Millwood). 2015;34(4):576-583.
4. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758-2765.
5. Behavioral Risk Factor Surveillance System. 2012 Summary Data Quality Report. http://www.cdc.gov/brfss/annual-data/2012/pdf/summarydataqualityreport2012-20130712.pdf. Published July 3, 2013. Accessed July 24, 2014.
6. Cho H, Klabunde CN, Yabroff KR, et al. Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies. Ann Intern Med. 2013;159(10):667-676.